ohm, oh boy! So assuming the new info continues to suggest that the disease can be fatal, the primary endpoint doesn't change, and CYDY is kept in the dark regarding the mortality rates of the 195 patients. Unless, of course, the DSMC stops the trial. But, at this point, I doubt that happens unless there are no deaths in the Lero arm. Even the FDA/DSMC might have to relent then.